AIDS Malignancy Consortium

Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study

Phase 2, Not yet recruiting, 2026, 43 people, 23 Jun 2026, clinicaltrials.gov

NCT05411237

Phase 3, Not yet recruiting, 2026, 130 people, 9 Jun 2022, clinicaltrials.gov

NCT04139304

Early phase 1, Recruiting, 2021, 15 people, 25 Oct 2019, clinicaltrials.gov

NCT03834571

Phase 2, Withdrawn, 2022, 0 people, 8 Feb 2019, clinicaltrials.gov

NCT02797470

Phase 1/2, Active, not recruiting, 2016, 11 people, 13 Jun 2016, clinicaltrials.gov

NCT01775475

Phase 2, Completed, 2016, 7 people, 25 Jan 2013, clinicaltrials.gov

NCT01590017

Phase 2, Completed, 2014, 41 people, 2 May 2012, clinicaltrials.gov

NCT01435018

Collaborator, Phase 3, Completed, 2013, 334 people, 15 Sept 2011, clinicaltrials.gov

NCT01249443

Phase 1, Terminated, 2013, 17 people, 29 Nov 2010, clinicaltrials.gov

NCT00598169

Phase 1, Completed, 2007, 23 people, 18 Jan 2008, clinicaltrials.gov

NCT00450320

Phase 1, Completed, 2007, 7 people, 22 Mar 2007, clinicaltrials.gov

NCT00392834

Phase 2, Completed, 2006, 34 people, 26 Oct 2006, clinicaltrials.gov

NCT00389818

Phase 2, Completed, 2007, 43 people, 19 Oct 2006, clinicaltrials.gov

NCT00310128

Phase 2, Withdrawn, 2006, 0 people, 3 Apr 2006, clinicaltrials.gov

NCT00041327

Phase 2, Completed, 2002, 19 people, 27 Jan 2003, clinicaltrials.gov